Amorfix achieves technical milestone in development of a blood test for Alzheimer's disease
07-Sep-2006
Pursuant to the subscription agreement executed January 30, 2006, OGI will now invest its second tranche of $50,000 in Amorfix. This transaction is subject to acceptance for filing by the TSX Venture Exchange.
Most read news
Organizations
Amorfix Life Sciences
Ontario Genomics Institute
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.